What's Happening?
Cure First, a Seattle-based 501(c)(3) nonprofit, is expanding its capacity to provide functional precision medicine for cancer patients, particularly those with hard-to-treat cancers. The organization plans to more than double its testing volume over
the next year, aiming to provide the PARIS Test to over 240 patients annually from its new lab in Bothell, Washington. This expansion includes hiring additional scientific staff to meet rising demand. The PARIS Test involves exposing a patient's live, biopsied tumor cells to various chemotherapies and targeted drugs to determine the most effective treatment. This approach has been deployed in 1,300 patient-derived tumor models across more than 40 cancer types, with studies demonstrating its feasibility and clinical utility. The expansion comes amid increasing adoption of functional precision medicine by oncologists and growing institutional support, including a clinical notice from the American Society of Clinical Oncology supporting its advancement.
Why It's Important?
This expansion by Cure First is crucial for U.S. cancer patients, especially those battling rare, treatment-resistant, late-stage, or metastatic cancers. Functional precision medicine, as offered by the PARIS Test, provides oncologists with critical data to inform treatment decisions, moving beyond traditional DNA-based biomarkers. This personalized approach can significantly improve patient outcomes by identifying therapies most likely to be effective, thereby reducing the trial-and-error period often associated with cancer treatment. For patients who have exhausted conventional options, this can offer a new path to remission, as demonstrated in published case reports. The increased capacity means more patients will have access to this advanced testing, potentially extending lives and improving quality of life. As a nonprofit, Cure First's reliance on philanthropic support highlights the current gaps in insurance coverage for such innovative treatments, underscoring the need for broader policy changes to ensure equitable access to cutting-edge cancer care.
What's Next?
Cure First aims to continue partnering with leading cancer centers, such as the University of Washington on the PROSPERITY study, to build clinical evidence supporting broader adoption of the PARIS Test. The organization will focus on advancing the clinical research needed to establish functional testing as a future standard of care. The increased testing capacity and additional scientific staff will enable Cure First to meet the growing demand for its services. The nonprofit will continue to rely on philanthropic support, including individual and corporate donations, to sustain access to the PARIS Test, as it is not yet widely covered by insurance. Ongoing research and published studies, like the one in Cancer Research Communications demonstrating the test's utility in biliary tract cancer, will further solidify the evidence base for this approach, potentially influencing future insurance coverage decisions and clinical guidelines.
Beyond the Headlines
The growth of functional precision medicine, exemplified by Cure First's expansion, represents a significant evolution in cancer treatment, moving towards highly individualized therapeutic strategies. This shift challenges the traditional one-size-fits-all approach to oncology and highlights the increasing sophistication of diagnostic tools. The ethical implications revolve around equitable access to such advanced testing, particularly given its current limited insurance coverage. This disparity could create a two-tiered system of care, where access is determined by financial means rather than medical need. Furthermore, the integration of complex data from functional tests into clinical practice requires ongoing education and training for oncologists. The long-term impact could be a fundamental redefinition of cancer care, with a greater emphasis on predictive testing and personalized treatment plans, potentially leading to higher success rates and a more efficient use of healthcare resources in the fight against cancer.
